37 results about "Lymphatic tissues" patented technology

A spore of a bacillus subtilis B.subtilis WB600 strain is used as an antigen delivery carrier, spore coat protein C (CotC) is used as anchoring protein, a key protein ATPase gene and a CotC gene of micropterus salmoides iridovirus are fused through a gene fusion technology, a recombinant spore surface display system is constructed, the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. After being orally applied to fishes, the vaccine can tolerate the gastrointestinal tract environment and is accurately delivered to intestinal related lymphatic tissues to stimulate fish immunity, and finally prevention and control of the iridovirus of the micropterus salmoides are achieved.

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

The invention discloses an intelligent classification and recognition method for ear-nose-throat lesion images, and relates to the technical field of image recognition, and the method comprises the steps: synchronously collecting a nasopharynx white light image and an i-Scan image, screening an image meeting a quality standard, carrying out the correlation of pathology and grading labeling, and constructing a data set containing a multi-center case; the white light image and the i-Scan image are subjected to denoising processing, key mark points are extracted, image registration is completed, a mucous membrane surface area, a submucous membrane blood vessel area and a lymphatic tissue enrichment area are divided through semantic segmentation, and feature enhancement is carried out on different areas; extracting morphological features and textural features from the enhanced image, calculating feature importance weights and fusing the feature importance weights into low-dimensional feature vectors; the benign and malignant dichotomy model and the pathological type multi-classification model are respectively constructed, and classification results are output in combination with a doctor diagnosis rule base and verification indexes, so that the accuracy and clinical practicability of ear-nose-throat lesion diagnosis are remarkably improved.

The invention provides pathological tissue section dyeing equipment and method. The method comprises the following steps: dividing a to-be-dyed lymphatic tissue section into a plurality of dyeing partitions according to the structural characteristics of lymphocyte tissues in the to-be-dyed lymphatic tissue section; dyeing agents with different concentrations are applied to different dyeing partitions according to the reference light transmittance of the lymphocyte tissue to obtain color gradient vectors of the lymphocyte tissue slices, light absorption characteristics of the dyeing partitions are measured through a photometer, and dyeing characteristics are determined based on the light absorption characteristics and the color gradient vectors; obtaining a dyeing image after dyeing the lymph tissue section, extracting deep features of the dyeing partitions from the dyeing image, and determining a dyeing loss value when dyeing the dyeing partitions based on the deep features and the dyeing features; and based on the dyeing loss value, carrying out self-adaptive adjustment on the dyeing agent concentration of each dyeing zone. By adopting the scheme provided by the invention, optimal adjustment on the concentration of the coloring agent in the sample dyeing process can be realized based on the characteristic difference of the cell tissues at different parts.

The invention discloses a ganoderma lucidum peptide for enhancing immunity as well as a preparation method and application thereof, and belongs to the technical field of functional peptide preparation. The ganoderma lucidum peptide provided by the invention contains various active ingredients / nutritional ingredients, is high in utilization rate of ganoderma lucidum, can improve the health level of intestinal tracts, promotes absorption and utilization of nutrient substances by the intestinal tracts, and provides a fundamental material guarantee for improving the immunity of the organism; immune cells are activated, and related lymphatic tissues of intestinal tracts are stimulated, so that the effects of regulating cellular immunity and humoral immunity levels are achieved; the preparation method provided by the invention does not use high-temperature, high-pressure and toxic and harmful reagents, has mild conditions, and is simple, easy to operate and environment-friendly; no toxic and harmful substances are generated, and generated filter residues can be directly used as animal feed or plant fertilizer; the prepared ganoderma lucidum peptide is small in molecule, high in activity, rich in active substance variety, high in yield and easy to absorb and utilize by organisms.

The invention discloses a culture method of in-vitro uniform monolayer cells of prawns, and belongs to the technical field of biology. The method comprises the following steps: (1) obtaining lymphatic tissues of a last-stage prawn at the early stage of shelling, completely stripping an outer membrane to obtain internal tissues, and cutting the internal tissues into small tissue blocks; (2) cleaning the small tissue blocks, inoculating the small tissue blocks to a culture plate coated with a gelatin solution, adding a complete culture solution into an inoculation system at intervals within 12 hours after inoculation for culture, replacing the complete culture solution 24-48 hours after inoculation, and inducing tissue cells to continuously migrate to form an in-vitro cell layer; (3) blowing and beating the cell culture to obtain a cell suspension, and centrifuging to obtain a cell monolayer; and (4) suspending the cell monolayer by adopting a complete culture solution, then inoculating the cell monolayer into a culture plate coated with a gelatin solution, and culturing to obtain the in-vitro uniform monolayer cells of the prawns. According to the method, the prawn monolayer cells which are long in in-vitro survival time, uniform and stable and are cultured in vitro can be obtained, and an important tool is provided for related virology research.

The present disclosure provides compositions and methods for the treatment and prevention of macrophage activation syndrome (MAS) or hemophagic lymphocyte hyperplasia (HLH). The methods involve administering to a patient in need thereof an antibody or fragment thereof that is specific for human GM-CSF protein.

One purpose of the present disclosure is to provide a technology for testing the presence or absence of a TLT in a subject without biopsy. Disclosed is a method for testing the presence or absence of a tertiary lymphoid tissue in a subject, the method including the step of measuring a soluble CD30 concentration in a blood sample collected from the subject.

Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal (GI) tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Disclosed herein is a vaccine comprising a nanoemulsion and an immunogen non-covalently conjugated to the surface of the nanoemulsion by an amphiphilic linker, wherein the vaccine is suitable for inducing a mucosal antibody response in the gastrointestinal tract. Also disclosed are methods of using the vaccine to immunize a subject by intraperitoneal administration of an effective amount of the vaccine, alone or with an adjuvant.

The invention relates to a kit for simultaneously detecting angiogenesis and plasma cell infiltration in lymphatic tissue and a preparation method and application of the kit, the kit comprises quantum well-antibody conjugates CQWs-525-VEGF, CQWs-525-ACTA2 and CQWs-585-CD138 and CQWs-625-Mum1, and the kit can be used for staining a lymphatic tissue section; by marking expression conditions of VEGF, ACTA2, CD138 and Mum1, the angiogenesis and plasma cell infiltration degree in the lymphatic tissue is evaluated. The quantum sheet has the characteristics of wide absorption spectrum, narrow light-emitting spectrum, high brightness and difficulty in quenching, and is used for marking blood vessels and plasma cells in tissues after being coupled with an antibody, so that quantitative analysis can be realized and spatial position distribution can be observed at the same time, the immune microenvironment of the tissues can be more accurately and effectively detected, and the immune state and immune function of the organism can be further evaluated.

A three-dimensional (3D) lymphoid tissue model is provided, the model including a cellularized stromal compartment and a plurality of cellularized compartments including lymphocytes disposed within the stromal compartment; and a controlled fluid perfusion system configured to perfuse the model with a perfusion fluid. Methods of fabricating a 3D lymphoid tissue model and producing antibodies with the 3D lymphoid tissue model are also provided.

The rapid lymphatic vein communication device comprises an elastic tube body, notches which are symmetrical left and right are formed in the front end of the tube body, the notches are in the shape with the large front portion and the small rear portion, the tube thickness of the notch areas is sequentially decreased from back to front, the section of the tube body is in an oval shape, and the section of the tube body is in an oval shape. The upper end and the lower end of the tube body are provided with sheet-shaped protrusions on the right side of the notch, and lymphatic vessel generation promoting factors are embedded or coated on the tube wall of the tube body. According to the invention, lymphatic tissues and veins can be communicated efficiently and quickly; blood reflux and thrombosis are avoided; sewing operation is not needed or reduced; blood vessel blocking is not needed; specific growth factors contained in the kit can promote the generation of normal lymph lumen, form autologous biological lumen in the later period, and maintain long-term smoothness.

The present disclosure provides, inter alia, compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring. Methods of preparing and using these drug-containing polymeric particles are also provided.

The invention provides a composite hydrogel for lymphatic tissue repair, which is formed by photo-crosslinking a gelatin-dopamine hydrogel capable of being subjected to methacrylic acid esterification, a lymph node acellular matrix and a photo-crosslinking initiator. The invention also provides a preparation method of the composite hydrogel, a re-cellularized hydrogel and application of the composite hydrogel and the re-cellularized hydrogel in preparation of a material for treating lymphatic tissue defects. By compounding the lymph node acellular matrix and the photo-crosslinkable gelatin dopamine hydrogel, a stent carrier which has natural biological signals, is suitable for a three-dimensional microenvironment and has good mechanical properties and in-situ forming characteristics is constructed, and an ideal platform is provided for field planting, growth and function exertion of ADSCs at a lymphatic tissue defect part; the ADSCs are assisted to play a repairing role in promoting lymphatic vessel regeneration and regulating a local microenvironment, and a novel composite hydrogel stent system adaptive to a cell repairing function is provided for treatment of related diseases such as lymphedema.

The utility model discloses a pair of curved claw separating forceps for endoscopic thyroid surgery. The pair of curved claw separating forceps comprises an operating rod, a movable forceps head, a fixed forceps head and a moving component, the first end of the fixed tong head is connected with the operating rod, the first end of the movable tong head is connected with the first end of the moving assembly, and the second end of the moving assembly is connected with the operating rod. The movable tong head comprises a first fixing rod, a first connecting rod and a first separating rod, the first end of the first fixing rod is connected with the moving assembly, the first end of the first connecting rod is horizontally connected with the second end of the first fixing rod in a bent mode, and the second end of the first connecting rod is vertically connected with the first separating rod in a bent mode. During use, the fixed forceps head and the movable forceps head are moved between the esophagus and the trachea, the movable forceps head is moved through the moving assembly so as to increase or decrease the distance between the movable forceps head and the fixed forceps head, fat and lymphatic tissue between the trachea and the esophagus are accurately clamped and separated, and the requirement of a cervical side thyroid surgery is met; and the operation efficiency is improved.

The invention relates to a lymphatic tissue targeted composite nanocluster as well as a preparation method and application thereof. The composite nanocluster comprises Se-doped ZnS nanoparticles and BSA (Bovine Serum Albumin) coated on the surfaces of the nanoparticles. The nano platform for synergistically targeting lymphatic tissues integrates the complementary immunoregulation functions of zinc and selenium, overcomes the curative effect limitation of a single element through the synergistic effect of elements, and widens the safe treatment window of necessary trace elements; the natural lymph targeting characteristic of the serum albumin is utilized to realize efficient lymph node delivery of the nanocluster; meanwhile, the nano-cluster structure can promote in-vivo removal, so that long-term accumulation is reduced, and the safety is ensured.

This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).

The invention discloses a nasal delivery double-chain RNA / Mn < 2 + > nano-drug as well as a preparation method and application thereof in immunotherapy. And adding the polymer into a solution containing double-stranded RNA and manganese salt, and self-assembling to form the nasal delivery double-stranded RNA / Mn < 2 + > nano-drug. The invention provides a new technical scheme for the barrier of the BBB. The nano delivery system has the advantages in the aspects of overcoming the BBB and improving the in-vivo biological distribution of the drug, and the surface of the nano carrier is modified with a ligand targeted to an endothelial cell overexpression receptor, such as ApoE peptide and the like, so that the drug can be delivered to penetrate through the BBB; a non-invasive nasal-brain delivery strategy becomes a new scheme for improving drug availability and reducing toxic and side effects, the drug can bypass BBB and rapidly enter brain parenchyma through olfactory bulb and trigeminal nerve conduction pathways, and an immune drug delivered by the nasal cavity can rapidly enter nasopharynx-related lymphatic tissue (NALT) and is transferred to CLN through a lymphatic network around the nasal cavity, so that the immune drug can be rapidly delivered to the nasopharynx-related lymphatic tissue (NALT). Further, a potent local immune response aiming at the in-situ GBM is induced.

One purpose of the present disclosure is to provide a technique for checking the presence or absence of tertiary lymphatic tissue in a subject without relying on biological tissue diagnosis. A method for testing the presence or absence of a tertiary lymphatic tissue in a subject, said method comprising a step for measuring the glutathione concentration in a bodily fluid sample collected from the subject.

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

A method for intranasal delivery of a formulation comprising Botulinum toxin for the treatment of allergic rhinitis involved impregnating an absorbent tip of an applicator with the formulation, the applicator having a rigid rod having the absorbent tip at a distal end thereof, and inserting the applicator straight into a nasal cavity of a patient beneath the lower turbinates to target the nasal- or nasopharynx-associated lymphoid tissue (NALT) and the eustachian tube opening zone of the nasopharynx within the nasal cavity with the absorbent tip.

The invention relates to an EB (Epstein-Barr) virus infected lymphoid tissue epithelial-mesenchymal transition detection kit as well as a preparation method and application thereof. The EB virus infected lymphoid tissue epithelial-mesenchymal transition detection kit comprises a colloidal quantum well labeled probe EBER, a colloidal quantum well labeled antibody CLDN4 and a colloidal quantum well labeled antibody N-cadherin, a colloidal quantum well-probe / antibody conjugate is used for sequentially dyeing a lymphatic tissue section and marking EMT-related antigens expressed in the section, so that the qualitative or quantitative treatment of the colloidal quantum well on the lymphatic tissue cells with EMT is realized, and the comprehensive evaluation on the virus infection state, the epithelial-mesenchymal transition process and the influence of the immune function of the lymphatic tissue cells can be realized.

This invention belongs to the field of biomedical technology and discloses the application of CCR2 inhibitors in the preparation of drugs for treating hemophagocytic lymphohistiocytosis (HLH). By establishing a mouse model of HLH, this invention reveals for the first time that CCR2 can serve as an effective drug target for treating HLH. Experiments showed that treatment with the CCR2-specific antagonist RS102895 significantly reduced splenomegaly, improved peripheral blood cell reduction, alleviated liver damage, corrected metabolic disorders in model mice, and effectively inhibited serum cytokine storm and abnormal activation of splenic macrophages. Based on these findings, CCR2 can serve as a novel target for HLH treatment, and its inhibitors can be used to prepare highly effective and low-toxicity drugs for treating HLH.

The present application relates to a kind of detection kits for EB virus and plasma cell in lymphoid tissue microenvironment and its preparation method and application, kit includes colloidal quantum well labeled probe EBER, colloidal quantum well labeled antibody CD138 and colloidal quantum well labeled antibody MUM-1;By colloidal quantum well and specific antibody conjugate to thymoma paraffin section sample dyeing, conjugate can be expressed with EBER and related antigen specific connection in section, so as to realize colloidal quantum well to lymphoid tissue, EB virus and the quantity and spatial position detection of plasma cell.Colloidal quantum well replaces fluorescent dye, can realize the direct marking of tissue section, realizes the local positioning of EB virus and plasma cell in lymphoid tissue microenvironment, both can realize the detection of quantity also can realize the detection of position, it is convenient to evaluate the situation of plasma cell in EB virus infection tissue microenvironment.

The application discloses an intelligent classification and identification method for ear-nose-throat lesion images, and relates to the technical field of image recognition, comprising the following steps: synchronously collecting a nasopharynx white light image and an i-Scan image, screening images meeting quality standards, associating pathology and grading annotation, and constructing a data set containing multi-center cases; carrying out denoising processing on the white light image and the i-Scan image respectively, extracting key landmark points and completing image registration, dividing mucosa surface area, submucosal blood vessel area and lymph tissue enrichment area through semantic segmentation, and carrying out feature enhancement on different areas; extracting morphological features and texture features from the enhanced images, calculating feature importance weights and fusing into low-dimensional feature vectors; constructing a benign and malignant binary classification model and a pathology type multi-classification model respectively, combining a physician diagnosis rule base and a verification index to output a classification result, and significantly improving the accuracy and clinical practicability of ear-nose-throat lesion diagnosis.

The invention discloses application of a conjunctiva-related lymphatic tissue index in diagnosis of dry eyes with sicca syndrome, and relates to the technical field of medical detection. A living body confocal microscope is used for observing and analyzing the morphological change of the conjunctival-related lymphatic tissue, a diagnostic model is established so as to assist in diagnosing SSDE, and the establishment method of the diagnostic model comprises the following steps: S1, preparing a subject; s2, IVCM inspection is carried out; s3, image processing and analysis; s4, data analysis; and S5, constructing a diagnosis model. Compared with the high cost of SS examination of all dry eye patients in referral, the method has the advantages that the CALT indexes are examined through IVCM, the patients needing to be further evaluated can be preliminarily screened out, and therefore unnecessary medical expenditure is reduced.

The present application relates to a kind of EB virus infection lymphatic epithelial-mesenchymal transition detection kit and its preparation method and application, including colloidal quantum well labeled probe EBER, colloidal quantum well labeled antibody CLDN4, colloidal quantum well labeled antibody N-cadherin;By colloidal quantum well-probe / antibody conjugate in turn to the staining of lymphatic tissue section, the EMT-related antigen expressed in section is marked, so as to realize colloidal quantum well to the qualitative or quantitative of lymphatic tissue cell that EMT occurs, can realize the comprehensive evaluation to virus infection state, epithelial-mesenchymal transition process and its immune function influence.

The present invention relates to the diagnosis and treatment of conditions in patients with elevated levels of CXCL9 and other biomarkers. Methods and compositions for the treatment of hemophagocytic lymphocytosis (HLH) are provided. The present disclosure also generally relates to methods and compositions for diagnosing and treating conditions associated with elevated levels of CXCL9, elevated levels of total IFN gamma, and other biomarkers. The present disclosure also relates to methods of treating, delaying the progression or otherwise ameliorating the symptom of a condition in a patient with elevated levels of CXCL9, elevated levels of total IFN gamma and other biomarkers using agents that intervene in or otherwise antagonize interferon gamma (IFN gamma) signaling, including neutralizing anti-IFN gamma antibodies.

To provide a pharmaceutical composition for use in the treatment of a disease selected from sepsis, secondary hemophagocytic lymphohistiocytosis, cytokine release syndrome, and systemic inflammatory response syndrome in a mammal in need thereof.SOLUTION: Provided is a pharmaceutical composition comprising a BTK inhibitor that is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.SELECTED DRAWING: None